228 related articles for article (PubMed ID: 31937234)
41. In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function.
Wang D; Starr R; Alizadeh D; Yang X; Forman SJ; Brown CE
J Vis Exp; 2019 Feb; (144):. PubMed ID: 30882787
[TBL] [Abstract][Full Text] [Related]
42. [Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines].
Deng HB; Liu MJ; Jiang YY; Yuan T; Zhang R; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):747-751. PubMed ID: 34753229
[No Abstract] [Full Text] [Related]
43. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Hillerdal V; Ramachandran M; Leja J; Essand M
BMC Cancer; 2014 Jan; 14():30. PubMed ID: 24438073
[TBL] [Abstract][Full Text] [Related]
44. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
45. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
[TBL] [Abstract][Full Text] [Related]
46. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
Han X; Cinay GE; Zhao Y; Guo Y; Zhang X; Wang P
Mol Ther; 2017 Nov; 25(11):2466-2476. PubMed ID: 28784559
[TBL] [Abstract][Full Text] [Related]
47. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
48. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
[TBL] [Abstract][Full Text] [Related]
49. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
50. Quantifying the limits of CAR T-cell delivery in mice and men.
Brown LV; Gaffney EA; Ager A; Wagg J; Coles MC
J R Soc Interface; 2021 Mar; 18(176):20201013. PubMed ID: 33653113
[TBL] [Abstract][Full Text] [Related]
51. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
Xu C; Yin Y
Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
[TBL] [Abstract][Full Text] [Related]
52. [Chimeric antigen receptors (CARs): universal tools in adoptive cell therapy].
Holzinger A; Abken H
Internist (Berl); 2021 Jun; 62(6):583-588. PubMed ID: 33928413
[TBL] [Abstract][Full Text] [Related]
53. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
54. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells].
Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075
[No Abstract] [Full Text] [Related]
55. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
[TBL] [Abstract][Full Text] [Related]
56. Preclinical testing of CAR T cells in zebrafish xenografts.
Grissenberger S; Salzer B; Pascoal S; Wenninger-Weinzierl A; Lehner M; Distel M
Methods Cell Biol; 2022; 167():133-147. PubMed ID: 35152991
[TBL] [Abstract][Full Text] [Related]
57. Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy.
Zhang Y; Wang P; Wang T; Fang Y; Ding Y; Qian Q
J Transl Med; 2021 Feb; 19(1):82. PubMed ID: 33602263
[TBL] [Abstract][Full Text] [Related]
58. Generation of CAR-T cells using lentiviral vectors.
Poorebrahim M; Quiros-Fernandez I; Fakhr E; Cid-Arregui A
Methods Cell Biol; 2022; 167():39-69. PubMed ID: 35152998
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
60. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
